Tarsus Pharmaceuticals, Inc. TARS Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease liabilities (total) of $16.08M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total) increased by 4087.2% year-over-year, from $384K to $16.08M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total) has grown at a 66.4% compound annual growth rate (CAGR), from $831K to $10.6M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.